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Abstract Tissue engineering is a promising technique for
cartilage repair. Toward this goal, a porous collagen–gly-
cosaminoglycan (CG) scaffold was loaded with different
concentrations of insulin-like growth factor-1 (IGF-1) and
evaluated as a growth factor delivery device. The biolog-
ical response was assessed by monitoring the amount of
type II collagen and proteoglycan synthesised by the
chondrocytes seeded within the scaffolds. IGF-1 release
was dependent on the IGF-1 loading concentration used to
adsorb IGF-1 onto the CG scaffolds and the amount of
IGF-1 released into the media was highest at day 4. This
initial IGF-1 release could be modelled using linear
regression analysis. Osteoarthritic (OA) chondrocytes see-
ded within scaffolds containing adsorbed IGF-1 deposited
decorin and type II collagen in a dose dependent manner
and the highest type II collagen deposition was achieved
via loading the scaffold with 50 lg/ml IGF-1. Cells seeded
within the IGF-1 loaded scaffolds also deposited more
extracellular matrix than the no growth factor control group
thus the IGF-1 released from the scaffold remained bio-
active and exerted an anabolic effect on OA chondrocytes.
The effectiveness of adsorbing IGF-1 onto the scaffold may
be due to protection of the molecule from proteolytic
digestion allowing a more sustained release of IGF-1 over
time compared to adding multiple doses of exogenous
growth factor. Incorporating IGF-1 into the CG scaffold
provided an initial therapeutic burst release of IGF-1 which
is beneficial in initiating ECM deposition and repair in this
in vitro model and shows potential for developing this
delivery device in vivo.
1 Introduction
The unique biomechanical properties of articular cartilage
are attributed to the complex zonal arrangement of its
constituent macromolecules, collagen and proteoglycan.
Cells known as chondrocytes synthesise and maintain the
extracellular matrix (ECM) which enables movement
under almost frictionless and wear resistant conditions [4].
Articular cartilage defects are common and present a major
risk factor in the development of osteoarthritis (OA) in
later life, yet articular cartilage has a limited capacity for
self-repair. Moreover, surgical treatment of cartilage
defects mainly yields suboptimal fibrous repair tissue.
Inadequate cartilage repair tissue fails to withstand the
biomechanical forces acting on the joint and degrades over
time hence much research has focused on utilising tissue
engineering strategies to yield a fully functional, long
lasting repair tissue [46]. Tissue engineering is the per-
suasion of the body to heal itself through the delivery of
cells, biomolecules and scaffolds [55]. Towards this goal,
this research describes loading a collagen–glycosamino-
glycan (CG) scaffold with bioactive molecules and cells to
enhance articular cartilage regeneration within an in vitro
model.
Scaffold design has centred on developing ECM matrix
analogues. Scaffold microstructure significantly affects cell
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adhesion, migration and proliferation within the matrix [8].
For cartilage tissue engineering, highly porous scaffolds
with large surface areas and adequate mechanical strength
are desirable, while a pore size of 100–500 lm has been
reported to be optimal for this repair [8, 15, 22, 23, 41].
The CG scaffold used in this study is composed of type I
collagen and chondroitin sulphate which is chemically
cross-linked to enhance its mechanical properties and
freeze-dried to create a porous microstructure. The CG
scaffolds possess highly interconnected porous architec-
tures with an average pore size of 216 ± 39 lm [38]. CG
scaffolds are promising regeneration templates for many
different tissues including; tendon, meniscal tissue, con-
junctiva, heart valves, tendon and ligaments [3, 6, 18, 20,
35, 44]. The most extensive research has focused on skin
and peripheral nerve regeneration and has yielded sub-
stantial success, as demonstrated by FDA approval [56].
Collagen is a key component of many biomedical devices,
while the chondroitin sulphate within the scaffold provides
compressive resistance and a microenvironment for cells
that is similar to native tissue. In vivo, cell–ECM interac-
tions provide adequate signals to cells to induce or main-
tain a desired state of cell differentiation. Growth factors
are soluble proteins which stimulate cell proliferation and
differentiation and can be used to aid cell migration, and to
increase matrix production [18, 23, 47]. Thus these proteins
play an important role in in vitro tissue engineering [53]
and may need to be added exogenously to achieve optimal
tissue repair.
Mature chondrocytes exhibit high metabolic activity and
characteristically synthesise type II collagen and large
aggregating proteoglycans such as aggrecan [4]. The ability
of chondrocytes to maintain the metabolic homeostasis of
the matrix decreases with ages [5, 7, 32]. Characteristics of
these aged chondrocytes include; the synthesis of smaller,
less regular aggrecan, reduced proteoglycan synthesis,
telomere shortening and a diminished response to insulin-
like growth factor (IGF-1) [31, 33]. Osteoarthritic chon-
drocytes possess a significantly lower proliferative activity
than normal chondrocytes [1, 21, 30] and poor respon-
siveness to growth factors [37]. However, human articular
chondrocytes can be isolated from mature articular carti-
lage via enzymatic digestion and expanded in vitro. Their
expression of type II collagen and proteoglycan demon-
strates that they partially maintain their phenotype [25] and
a study of a micromass pellet culture of human OA
chondrocyte indicated that these chondrocytes are capable
of differentiation and proliferation in vitro comparable with
normal chondrocytes for 14 days [49]. Furthermore, in
human cartilage specimens with advanced OA some
chondrocytes continue to express link protein and type II
collagen mRNA, indicating that they have remained ana-
bolically active [2]. Therefore it was of interest to us into
establish whether IGF-1 would enhance the OA chondro-
cytes phenotype when delivered via a biomimetic scaffold.
IGF-1, an anabolic growth factor involved in cartilage
development and homeostasis [12, 51] has been exten-
sively investigated for use in articular cartilage repair [10,
12, 17, 34, 40, 51]. Fortier et al. [12] demonstrated that the
addition of 10–100 ng/ml IGF-1 enhanced the levels of
proteoglycan and type II collagen synthesised by chon-
drocytes seeded in fibrin matrices and that the cells main-
tained their phenotype in vitro. In addition, IGF-1 also
protects the ECM from interleukin-1 (IL-1) and tumour
necrosis factor a-mediated degradation during cartilage
injury [14, 16, 52]. In vivo, IGF-1 loaded fibrin matrices
have been used to repair full thickness articular cartilage
defects in horses [44]. These loaded matrices enhanced the
formation of hyaline like repair tissue and had better
adhesion to the subchondral bone compared to controls.
Moreover, Tuncel et al. [51] reported that collagen sponges
loaded with 5 lg IGF-1 enhanced the tissue response and
produced significantly better quality neocartilage compared
with the collagen sponge controls in a rabbit osteochondral
defect model. Madry et al. [34] demonstrated that scaffolds
filled with IGF-I-over-expressing chondrocytes yielded
markedly improved osteochondral repair compared with
control scaffolds.
IGF-1 plays a key role in articular cartilage maintenance
during adult life; stimulating matrix protein production and
inhibiting degradation and cell death [28, 29, 50]. The
addition of exogenous IGF-1 to chondrocytes and articular
cartilage explants blocks the IL-1 induced degradation of
proteoglycans and aids chondrocyte survival [14, 24]. Low
levels of IGF-1 are present in normal articular cartilage
[36]. The effect of IGF-1 on articular cartilage is modu-
lated during ageing and OA, resulting in reduced anabolism
and an increase in matrix degradation. Schneiderman et al.
[48] investigated the distribution of IGF-1 in normal and
OA cartilage and found that in OA cartilage the concen-
tration of all forms of IGF are higher and lie in the range
necessary for the anabolic stimulation of chondrocytes.
However, higher levels of IGF binding proteins (IGFBPs)
have been found in OA chondrocytes and cartilage com-
pared to those found in normal tissue and cells [11, 43].
This evidence suggests that the high levels of IGFBPs may
be responsible for the hyporesponsiveness of OA chon-
drocytes to IGF-1.
IGF-1 was incorporated into the CG scaffold via sorp-
tion with aim to achieve the release of a therapeutic release
of IGF-1 that would yield de novo hyaline articular carti-
lage tissue in vitro. This study aims to evaluate this scaf-
fold as a growth factor delivery device and to assess the
biological response in terms of the articular cartilage ECM
proteins synthesised by the seeded chondrocytes. The
binding and release of IGF-1 from the CG scaffold has
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been previously monitored using a radiolabeled method
and the release profile was monitored over 14 days [9].
This study indicated that ionic interactions contribute to the
binding and a burst release of IGF-1 occurred up to 24 h,
followed by sustained release up to day 14. In the present
study the amount of extracellular matrix proteins (type II
collagen and proteoglycan) in the media or laid down on
the scaffold were measured to assess the new ECM pro-
duction within the model. CG scaffolds were also loaded
using different IGF-1 loading concentrations (25, 50,
100 lg/ml IGF-1) to compare the biological effect on OA
chondrocytes of the incorporation and release of different
amounts of IGF-1 into the scaffold.
2 Materials and methods
2.1 Materials
2.1.1 CG scaffolds and cell culture
Type I insoluble collagen prepared from bovine skin
(Devro Plc), and chondroitin-6-sulphate (Bioiberica) were
used to prepare collagen–GAG scaffolds. 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) were purchased from Sigma
Aldrich. Human recombinant IGF-1 was purchased from
R&D Systems. Human chondrocytes were derived from
knee articular cartilage donated from patients (N = 3)
undergoing total knee replacement surgery with full ethical
consent 06/Q0108/213. Full depth articular cartilage was
removed from femoral condyles and tibial plateaux using a
scalpel. The tissue was then minced finely before incu-
bating in a 0.2 % (w/v) solution of bacterial collagenase
(Roche) in complete medium (DMEM, 10 % FCS plus
antibiotics) overnight at 37 C. Released cells were washed
twice to remove any collagenase before plating on plastic.
Chondrocytes were expanded and used at passage three in
order to retain as much of the chondrogenic phenotype as
possible. All experiments were carried out using cells
derived from N = 3 individual donors.
2.1.2 Protein detection
Primary antibodies: collagen II: AVT6E3 (mouse mono-
clonal, kind gift from Anne Vaughan Thomas, University
of Cardiff), decorin: (AF143, R&D Systems). Secondary
antibodies (Sigma), anti-mouse peroxidase conjugated IgG
(A0168, Sigma), anti-goat peroxidase conjugated IgG
(A4174). Standards: Collagen II: human collagen II pre-
pared by pepsinisation and salt fractionation from osteo-
arthritic knees from patients undergoing total joint
replacement with full ethical consent, Recombinant
decorin (Cat no. 143-DE, R&D systems). Immobilon
PVDF (Millipore) membranes were used for western
blotting. 1,9- Dimethyl-methylene blue (DMMB) was
purchased from Sigma-Aldrich.
2.2 Methods
2.2.1 Scaffold preparation
Collagen was added to an aqueous HCl solution (0.001 M)
and left to swell overnight (17–20 h at 4 C) to give a final
concentration of 0.9 wt% collagen. The collagen slurry was
blended for 1 h using a high energy blender (Turax (VWR
Int.)) and cooling on ice. Chondroitin-6-sulphate (GAG)
was dissolved in 0.001 M HCl, then added (0.08 wt%) and
the slurry was blended for a further 30 min. The blended
slurry was poured into glass moulds and freeze-dried
(Virtis Advantage ES), using a constant cooling rate of
0.01 C/min and a final freezing temperature of -12 C.
The discs were then chemically cross-linked using EDC/
NHS/COOH at a molar ratio of 5:2:1 [6] and then freeze-
dried using the same freeze-drying process. Final scaffold
discs were 5 9 2 mm2 and weighed 1.5 ± 0.1 mg.
2.2.2 Cell culture
CG scaffolds were either incubated in media containing
IGF-1 (25, 50 or 100 lg/ml) or media only for 24 h at
37 C. The scaffolds were then rinsed and each scaffold
was then seeded with 1 9 105 primary OA chondrocytes
which were allowed to attach to the scaffold for 2–3 h in
media containing FCS (10 %) before continuing culture in
0.5 ml media for up to 14 days.
2.2.3 Measurement of released IGF-1
The IGF-1 released into the media from the scaffolds was
measured using a Quantikine DG100 ELISA kit (R&D
Systems) as described in the manufacturer’s instructions.
Media samples from days 4, 7, 11, 14 were added to wells
pre-coated with an antibody specific for IGF-1, washed
(PBST) and incubated with peroxidase conjugated sec-
ondary antibody for 1 h. Further washing (PBST) was
followed by the addition of the substrate and the reaction
was stopped after 30 min by the addition of concentrated
H2SO4. The absorbance was measured immediately at
544 nm in a Fluostar optima plate reader. The average
amount of IGF-1 and standard error of the mean were used
to report cumulative IGF-1 release. The table displays the
average amount of IGF-1 released at each time point. The
IGF-1 release up to day 4 was replotted against the loading
concentration and linear regression analysis was
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performed, P \ 0.05 was considered to be statistically
significant.
2.2.4 DMMB assay
The total amount of proteoglycan synthesised by the cells
was measured using the 1,9-dimethyl-methylene blue
(DMMB) assay [7, 8]. Media samples (40 ll) from days 4,
7, 11, 14 of the experiment (N = 4) and CS standards
(40 ll) were added to a 96 well plate and 250 ll of DMMB
was added to each well. The absorbance was measured
immediately at 544 nm in a Fluostar optima plate reader.
The average amount of sulphated GAG and standard error
of the mean were reported and data from each IGF-1
loading concentration was compared using a two tailed
Student t test, P \ 0.05 was considered to be statistically
significant.
2.2.5 Western blotting
At each time point of the study scaffolds were removed and
300 ll of cell extraction buffer was added to each. These
samples were rotated overnight and 100 ll of SDS sample
buffer (49) was added to each sample followed by heating
at 60 C for 30 min. Proteins were separated by SDS gel
electrophoresis and Western blotted (N = 3 replicate
samples from N = 3 donors) before probing for decorin
and type II collagen. Specific bands for each protein were
quantified using densitometry and standard curves of pure
protein. The average amount of protein and standard error
of the mean were reported and data from each IGF-1
loading concentration was compared using a two tailed
Student t-test, P \ 0.05 was considered to be statistically
significant.
3 Results
3.1 IGF-1 released into the media
Scaffolds were loaded with different IGF-1 concentrations
prior to cell-seeding and the media was collected on days 4,
7, 11 and 14 of the experiment. The amount of IGF-1
present in this media was measured using an ELISA assay.
The release of IGF-1 for all loading groups was dominated
by the release that occurs up to day 4, where 60–231 ng/ml
IGF-1 was released compared with much lower release
(1–13 ng/ml) for all later time points (Table 1).
3.2 Sulphated GAG release into the media
Chondrocytes grown in scaffolds loaded with 50 and
100 lg/ml IGF-1 produced a significantly higher amount of
sulphated GAG in the media compared with the no growth
factor control group after 4 days (Fig. 1).
3.3 ECM deposition on the CG scaffold
3.3.1 Decorin
OA chondrocytes seeded with the scaffold demonstrated a
dose dependent response of decorin deposition to increas-
ing levels of IGF-1 (Fig. 2). This result was found to be
statisically significant (0 vs. 50, 0 vs. 100, P \ 0.05).
3.3.2 Type II collagen
Similarly the levels of type II collagen deposited in the
scaffold also responded positively to the IGF-1 that had
been bound to the scaffold (Fig. 3) In this case the highest
amount of type II collagen deposition was observed for
scaffolds loaded with 50 lg/ml IGF-1 and this was sig-
nificantly higher than the no growth factor control.
Table 1 The amount of IGF-1 (ng/ml) released over 14 days from
scaffolds loaded with each IGF-1 loading concentration
Time (Days) IGF-1 release (ng/ml)
IGF-1 loading Concentration (lg/ml)
25 SEM 50 SEM 100 SEM
4 60.18 5.41 120.82 12.13 230.66 18.35
7 2.68 0.23 8.11 1.46 13.05 0.89
11 0.73 0.04 2.51 0.51 4.17 0.38
14 0.21 0.09 1.10 0.10 1.11 0.08
Fig. 1 The amount of sulphated GAG released into the media (lg/
ml) for each IGF-1 loading group at day 4. The significant differences
(*P \ 0.05) between groups, N = 4. The error bars represent the
standard error of the mean
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4 Discussion
Previous studies have demonstrated that a steady or daily
growth factor action would be advantageous [26, 39, 42,
50] and that 10 ng/ml IGF-1 is sufficient to stimulate the
proliferative and metabolic activity of chondrocytes cul-
tured in vitro while proteoglycan production is at a maxi-
mum using a dose of 100 ng/ml IGF-1 [12, 54]. The
addition of IGF-1 to explants and monolayer cultures at
concentrations of 10–200 ng/ml increased collagen type II
DNA synthesis and inhibited proteoglycan degradation
while 200 ng/ml also inhibited chondrocyte apoptosis
in vitro [13, 27]. The benefit of adding different concen-
trations of endogenous IGF-1 (i.e. IGF-1 pre-loaded into
the scaffold) on ECM synthesis was evaluated by com-
paring the amount of sulphated GAG and in the media, and
the amounts of decorin and type II collagen deposited onto
each CG scaffold. ECM was measured at day 4 as this
corresponded with the highest release of IGF-1 from the
scaffold into the media (Table 1).
Cells seeded within the endogenous IGF-1 group pro-
duced the highest level of sulphated GAG release, com-
pared with the no growth factor control group (Fig. 1).
However, this assay does not distinguish between newly
synthesised sulphated GAG and the release of sulphated
GAG from the CG scaffold. The known properties of IGF-
1 would suggest that the increased release demonstrated in
this study is probably due to growth factor mediated syn-
thesis but in future, the incorporation of radiolabelled
sulphate (35S) would be a better detection method as it
would only detect newly synthesised sulphated GAG and
thus would provide a more sensitive assay for comparing
scaffold groups.
The OA chondrocytes from the IGF-1 groups yielded a
significantly higher amount of decorin deposition onto the
scaffold compared to the no growth factor control
(P \ 0.05) (Fig. 2). The results were similar to those
obtained by the addition of 10–50 ng/ml exogenous IGF-1
(i.e. growth factor added to the medium) (data not shown).
Therefore, one could speculate that the IGF-1 adsorbed
onto scaffolds in the endogenous IGF-1 group may release
at least 10–50 ng/ml IGF-1 within the first 4 days. The
principal band detected on the decorin western blot is of a
considerably higher molecular weight than purified
recombinant decorin which runs at approximately 43 kDa.
We achieve this pattern of bands on a routine basis whilst
working with either whole cartilage or matrix deposited by
chondrocytes in vitro. The recombinant standard used here
is the unglycosylated core protein whereas the molecule
Fig. 2 Decorin deposition on the Scaffold. a Western blot indicating
decorin deposited by OA chondrocytes within the scaffold 1 0 lg/ml
IGF-1, 2 25 lg/ml IGF-1, 3 50 lg/ml IGF-1, 4 100 lg/ml IGF-1, 5
Standard (recombinant decorin). b Quantification of western blot
shown in Fig. 3a by densitometry. The significant differences
(*P \ 0.05) between groups. N = 4. The error bars represent the
standard error of the mean
Fig. 3 Type II Collagen Deposition on the Scaffold a Type II
collagen Western Blot indicating the type II collagen deposited by
OA chondrocytes within the scaffold 1 0 lg/ml IGF-1, 2 25 lg/ml
IGF-1, 3 50 lg/ml IGF-1, 4 100 lg/ml IGF-1, 5 Standard (purified
human type II collagen). b Quantification of western blot shown in
(a) by densitometry. The significant differences (*P \ 0.05) between
groups. N = 3. The error bars represent the standard error of the
mean
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that we extract from our cultures or tissue is partly or fully
glycosylated with dermatan or chondroitin sulphate mole-
cules leading to the increased molecular weight [45]. De-
corin is also known to interact with a range of collagen
molecules [18–20] and it is possible that some of these
interactions also remain intact following our extraction
procedures. We have used decorin in preference to aggre-
can as a marker of proteoglycan synthesis to overcome the
difficulties in western blotting aggrecan caused by its large
molecular weight and lack of suitable antibodies.
Chondrocytes seeded within scaffolds pre-loaded with
IGF-1 produced type II collagen deposition on the scaffold
in a dose-dependent manner (Fig. 3). The effect of exog-
enous IGF-1 on type II collagen deposition was also
compared with endogenous IGF-1 and the highest amount
of type II collagen deposited onto the scaffold was found
for cells within scaffolds containing endogenous IGF-1
(data not shown). The highest type II collagen deposition in
this study was achieved via the addition of 50 lg/ml IGF-1
to the scaffold and deposition decreased as the IGF-1
concentration was increased to100 lg/ml. This trend may
be due to the reported decrease in IGF-1 receptor (IGF-1R)
mRNA levels induced by the addition of exogenous IGF-1
[9]. OA chondrocytes from older patients exhibit reduced
anabolism, a reduced response to IGF stimulation and
release higher levels of catabolic cytokines and IGFBPs.
IGFBPs may potentate IGF binding to its receptor but high
levels of these binding proteins facilitate the storage of
IGF-1 and complexed IGF cannot bind to its receptor
leading to hypo-responsiveness. Adding a high concentra-
tion of exogenous IGF-1 or IGF-1 bound to a scaffold may
be necessary to saturate the high levels of IGFBPs released
from these OA chondrocytes. Free IGF-1 has a short half
life, but at high levels it can bind to both the IGFR1 and
insulin receptor (IR) to exert an anabolic effect.
Adsorbing IGF-1 or other appropriate growth factors to
a scaffold may partially protect the growth factor from
degradation or inactivation allowing a longer anabolic
effect. The effectiveness of adsorbing IGF-1 onto the
scaffold may be due to protection of the molecule from
proteolytic digestion allowing a more sustained release of
IGF-1 over time compared to adding multiple doses of
exogenous IGF-1. Hortensius and Harley also demon-
strated a dose-dependent change in bioactivity to IGF-1
within CG scaffolds using an in vitro tenocyte model, this
indicates that the growth factor remained bioactive within
the matrix [19]. The stimulation of type II collagen pro-
duction implied that these IGF-1 loaded scaffolds released
a therapeutic dosage of IGF-1 which maintained the cell
phenotype and stimulated an anabolic response. However,
data for IGF-1 treatments taken at time points later than
day 4 (days 7, 11 and 14) did not demonstrate any signif-
icant differences in matrix deposition or release when
compared with controls (data not shown). This suggests
that the initial burst release of IGF-1has an effect on the
cells but continued treatment at therapeutic levels does not,
possibly due to the cells becoming refractory to continual
exposure to the IGF-1. Despite this lack of effect at later
time points, we believe that the increased levels of matrix
production seen at the early time point suggests that
binding IGF-1 to the scaffold may be beneficial by causing
a more rapid stimulation of the cells in order to initiate
extracellular matrix deposition and cartilage repair.
5 Conclusions
The release of IGF-1 from this system was dependent on
the IGF-1 loading concentration used to adsorb IGF-1 onto
the CG scaffolds. And the amount of IGF-1 released into
the media was highest at day 4. Relatively low levels of
IGF-1 measured in the media may be attributed to the
proteolytic degradation of free IGF-1, the degradation of
IGF-1 after binding to the IGFR1 or the role of the scaffold
and IGFBPs to act as an IGF-1 reservoir. OA chondrocytes
seeded within scaffolds containing adsorbed IGF-1
deposited decorin and type II collagen in a dose dependent
manner. The highest type II collagen deposition in this
study was achieved via loading the scaffold with 50 lg/ml
IGF-1. Cells seeded within the IGF-1 loaded scaffolds also
deposited more ECM than the control group proving that
the IGF-1 released from the scaffold remained bioactive
and exerted an anabolic effect. The effectiveness of
adsorbing IGF-1 onto the scaffold may be due to protection
of the molecule from proteolytic digestion allowing a more
sustained release of IGF-1 over time compared to adding
multiple doses of exogenous IGF-1. Incorporating IGF-1
into the CG scaffold provided an initial therapeutic burst
release of IGF-1 which is beneficial in initiating ECM
deposition and repair in this in vitro model and shows
potential for developing this delivery device in vivo.
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